Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.54 |
| ▸ | CNR2 | P34972 | 5/20 | 0.51 |
| ▸ | CNR1 | P21554 | 4/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL602524 | 0.83 | CNR2 (0.56) | PLA2G2ACNR2CNR1PTGER4NPC1 | |
| SCHEMBL600940 | 0.82 | PLA2G2A (0.57) | PLA2G2ACNR2CNR1PTGER4NPC1 | |
| SCHEMBL600236 | 0.80 | CNR2 (0.69) | PLA2G2ACNR2CNR1 | |
| SCHEMBL13471701 | 0.74 | PTGER4 (0.50) | CNR2PTGER4NPC1 | |
| SCHEMBL5808472 | 0.74 | PLA2G2A (0.73) | PLA2G2ACNR2CNR1 | |
| SCHEMBL27901716 | 0.73 | KMT2A (0.55) | PLA2G2A | |
| SCHEMBL601723 | 0.73 | CNR2 (0.52) | PLA2G2ACNR2CNR1NPC1RAB9A | |
| SCHEMBL7952544 | 0.71 | PLA2G2A (0.82) | PLA2G2ARAB9A | |
| SCHEMBL12355265 | 0.71 | MAPT (0.63) | DYRK1ARAB9A | |
| SCHEMBL7952825 | 0.71 | PLA2G2A (1.00) | PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | THE UNIV OF MONTANA (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | THE UNIV OF MONTANA (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | THE UNIV OF MONTANA (US) | 2017-04-06 | — | — | US | disclosed |
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | disclosed |
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | disclosed |
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039804-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | CNR1, CNR2, OPRL1 | PLA2G2A 1077/4885CNR2 2/4885CNR1 1/4885 |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | CNR1, CNR2, OPRL1 | PLA2G2A 1077/4885CNR2 2/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.